According to a story in the New York Times, drug maker Eil Liy, is negotiating with federal and state agencies to settle federal and state civil and criminal penalties regarding the marketing practices it employed for its anti-psychotic drug. Zyprexa gained FDA approval for treatment of people with schizophrenia and sever bipolar disorder. Evidence shows that Eil Lily marketed the drugs to doctors for other uses, including in people with age related dementia. Doctor are allowed to use drugs for off label purposes, but drug companies are not allowed to promote these uses. This fine would be the largeset one of its kind, if approved.
Eli Lily has already paid $1.2 Billion to settle lawsuits claiming Zyprexa causes diabetes in some who take it.